In this study, the authors used a combination of cross-sectional, retrospective, and prospective study designs on 95 estrogen receptor-positive and Her2 receptor negative stage II-III cancer patients treated at the Hanoi Oncology Hospital from January 1, 2015, to January 1, 2020.